Your Messages Inbox
Your Article Summary
See Latest ArticlesU.S. Army Botulinum Neurotoxin (BoNT) Medical Therapeutics Research Program: past accomplishments and future directions
Drug Development Research, 06/19/09
Larsen JC et al. - The development of small molecules for the treatment of BoNT has also been supported. Efforts have focused on molecules to inhibit nearly every aspect of BoNT pathogenesis. This would include toxin binding, translocation, catalytic activity, and recovery following intoxication. Several compounds capable of inhibiting toxin activity or mitigating the severity of paralysis have been identified.
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
AstraZeneca and the University of Virginia sign strategic research collaboration to develop novel treatments for cardiovascular disease
AstraZeneca, 12/16/09
Sanofi Pasteur expands study of vaccine against Clostridium difficile into the U.S.
Sanofi-aventis, 12/16/09
Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study
Amylin Pharmaceuticals, 12/16/09
Article Search
Sponsor